Pure Global AI
NCT05866510Recruiting

Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

A Multicenter, Single-arm, Exploratory Clinical Study of Utidelone Combined With Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer That Has Failed Standard First-line Therapy
Peking UniversityPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Esophageal Cancer
Drug/Device/Intervention
Utidelone and anlotinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Peking University
Location
Weihui,Suining,Beijing, China
Timeline & enrollment
Phase
Phase 2
Start date
May 15, 2023
End date
Apr 30, 2024
Enrollment
47 participants
Primary outcome

Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants

Summary

The goal of this clinical trial is to evaluate the safety, tolerance and efficacy of
 Utidelone combined with Anlotinib in patients with Advanced or Recurrent Esophageal Carcinoma
 who failed Standard first line therapy.

ICD-10 classifications
Carcinoma in situ: OesophagusMalignant neoplasm of oesophagusMalignant neoplasm: Middle third of oesophagusMalignant neoplasm: Overlapping lesion of oesophagusMalignant neoplasm: Upper third of oesophagus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05866510
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05866510 through Pure Global AI's free database. This Phase 2 trial is sponsored by Peking University and is currently Recruiting. The study focuses on Esophageal Cancer. Target enrollment is 47 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.